Repligen Corp (NASDAQ: RGEN) kicked off on Monday, down -3.81% from the previous trading day, before settling in for the closing price of $166.21. Over the past 52 weeks, RGEN has traded in a range of $113.50-$211.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 29.26% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -11.96%. With a float of $52.13 million, this company’s outstanding shares have now reached $56.03 million.
In an organization with 1783 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 46.88%, operating margin of -0.84%, and the pretax margin is -0.42%.
Repligen Corp (RGEN) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Repligen Corp is 6.96%, while institutional ownership is 100.19%. The most recent insider transaction that took place on Nov 21 ’24, was worth 3,386,439. In this transaction Director of this company sold 24,246 shares at a rate of $139.67, taking the stock ownership to the 139,840 shares. Before that another transaction happened on Nov 21 ’24, when Company’s Executive Chairman proposed sale 24,246 for $139.66, making the entire transaction worth $3,386,311.
Repligen Corp (RGEN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -11.96% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.30% during the next five years compared to 11.56% growth over the previous five years of trading.
Repligen Corp (NASDAQ: RGEN) Trading Performance Indicators
Take a look at Repligen Corp’s (RGEN) current performance indicators. Last quarter, stock had a quick ratio of 8.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.14. Likewise, its price to free cash flow for the trailing twelve months is 68.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.15, a number that is poised to hit 0.41 in the next quarter and is forecasted to reach 1.74 in one year’s time.
Technical Analysis of Repligen Corp (RGEN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.71 million. That was better than the volume of 0.58 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.96%. Additionally, its Average True Range was 7.24.
During the past 100 days, Repligen Corp’s (RGEN) raw stochastic average was set at 62.87%, which indicates a significant increase from 29.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.51% in the past 14 days, which was lower than the 46.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $153.35, while its 200-day Moving Average is $147.57. However, in the short run, Repligen Corp’s stock first resistance to watch stands at $163.38. Second resistance stands at $166.89. The third major resistance level sits at $168.68. If the price goes on to break the first support level at $158.07, it is likely to go to the next support level at $156.28. Assuming the price breaks the second support level, the third support level stands at $152.77.
Repligen Corp (NASDAQ: RGEN) Key Stats
The company with the Market Capitalisation of 8.96 billion has total of 56,027K Shares Outstanding. Its annual sales at the moment are 638,760 K in contrast with the sum of 41,580 K annual income. Company’s last quarter sales were recorded 154,870 K and last quarter income was -650 K.
